

GEOVAX LABS, INC.
Condensed Consolidated Statements of Operations Information
(amounts in thousands, except share and per share data)

	Three Months Ended March 31,	
	2020	2019
Grant and collaboration revenues	\$ 716	\$ 364
Operating expenses:		
Research and development	809	556
General and administrative	502	510
	1,311	1,066
Loss from operations	(595)	(702)
Other income (expense), net	(1)	1
Net loss	\$ (596)	\$ (701)
Net loss per common share	\$ (0.13)	\$(2,851.44)
Weighted average common shares outstanding	4,687,893	246

Condensed Consolidated Balance Sheet Information
(amounts in thousands)

	March 31, 2020	Dec. 31, 2019
Assets:		
Cash and cash equivalents	\$ 222	\$ 283
Other current assets	588	164
Total current assets	810	447
Property and other assets, net	21	22
Total assets	\$ 831	\$ 469
Liabilities and stockholders' equity (deficiency)		
Total liabilities	\$ 2,695	\$ 2,043
Stockholders' equity (deficiency)	(1,864)	(1,574)
Total liabilities and stockholders' equity (deficiency)	\$ 831	\$ 469
Common Shares Outstanding	13,791,601	299,835